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of adverse events (NAE); extrapyramidal symptoms (EPS); weight gain (WG); and 
sexual dysfunction (SD). The transition probabilities amongst health states were 
estimated from two different meta-analysis of clinical trials and from a retrospective 
Spanish study. The health care costs associated to each health state were obtained 
from a published Spanish study. It was used the minimum acquisition cost per mg. of 
the mean daily dose, for each AA, which is regarded as a relevant efﬁ ciency criterion 
in Hospital Pharmacy Departments. The time horizon applied in the analysis was 12 
months. a probabilistic sensitivity analysis was performed for all the variables involved 
in the analysis via Monte Carlo simulations. All costs were inﬂ ated to 2009 costs using 
Spanish Health System pay and prices index. RESULTS: In comparison with OLA, the 
treatment with ARI generates annual average cost savings per patient of c−688.70 ± 
21.69 (CI 95% −614.52; −729.18). In the most unfavourable scenario for ARI, that in 
which we assumed that ARI may have a similar rate of sexual dysfunction than that of 
quetiapine (i.e. the lowest rate amongst AA) the costs savings per patient would be 
c–270,94 ± 17,11 (CI 95% −237,20; −303,48). CONCLUSIONS: The results of this 
analysis show that patients treated with aripiprazole demonstrate lower adverse events 
costs in comparison to olanzapine. This difference may generate signiﬁ cant cost 
savings to the Spanish health system in the treatment of patients affected by bipolar 
disorders. The robustness of the results was tested via a probabilistic sensitivity 
analysis.
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OBJECTIVES: Real-world treatment patterns and health care resource utilization for 
patients with GAD in the United States are not fully deﬁ ned. METHODS: Data from 
the 2003–2007 Thomson Reuters MarketScan® Commercial Claims and Encounters 
and Medicare Supplemental and Coordination of Beneﬁ ts databases were utilised for 
analysis. For the current analysis, participants with a diagnosis of GAD (ICD-9 CM 
300.02) between January 1, 2004 and December 31, 2006 were included. The sample 
was divided into the following ﬁ ve subgroups: patients receiving non-pharmacological 
treatment, ﬁ rst-line therapy only, ﬁ rst-line + augmentation within 90 days of index 
prescription, ﬁ rst-line + switch within 90 days of index prescription and second-line 
therapy only. Additionally, GAD patients were compared with healthy controls 
without GAD or other mental health conditions. RESULTS: In total, 23,553 GAD 
patients (mean age range: 41.6–48.1 years; 56.1–68.6% female across the ﬁ ve groups) 
were included (non-pharmacological, n = 7055; ﬁ rst-line only, n = 6538; ﬁ rst-line + 
augmentation, n = 903; ﬁ rst-line + switch, n = 1953; second-line only, n = 7104). 
Paroxetine was the most commonly used ﬁ rst-line treatment at index (ﬁ rst-line cohorts: 
48%, 42%, 41%, respectively). In the second-line only cohort, a benzodiazepine 
(37%) or second-line SSRI/SNRI (27%) were the most commonly used agents at index. 
Benzodiazepines were the most commonly prescribed agents for augmentation of, or 
switching from, ﬁ rst-line treatments (augmentation 52%, switch 44%). Overall, GAD 
patients had higher health care utilization and signiﬁ cantly higher total health care 
costs versus healthy controls (mean per patient: $8058 vs. $2938, P < 0.0001). On 
average, GAD patients incurred an additional $425/month in direct health care costs 
in the 1-year post-index period versus healthy controls. CONCLUSIONS: The real-
world management of GAD is both complex and costly. Paroxetine was the most-
widely used ﬁ rst-line treatment for GAD. Benzodiazepines were the most widely used 
agents for augmentation of, or switching from, ﬁ rst-line treatments, and for second-
line therapy. Total health care costs were 2.7 times higher for GAD patients compared 
with healthy controls.
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OBJECTIVES: There is a paucity of published evidence estimating the economic and 
humanistic burden of illness in GAD. We report results of a retrospective database 
analysis examining the burden of GAD in Europe. METHODS: Data were derived 
from the European (France, Germany, UK, Italy, Spain) National Health and Wellness 
Survey database for 2008. The database captures information from adults (≥18 years) 
and is representative of the adult population in each country. Respondents reporting 
a diagnosis of GAD were propensity-score matched 1:1 to non-GAD controls on 
country, age, gender and employment status. Data were extracted on GAD medication 
use, resource utilization (emergency room visits, hospitalizations and health care 
provider visits) and work productivity (using the Work Productivity and Activity 
Impairment questionnaire) to calculate direct and indirect costs. Health-related quality 
of life (HRQoL) was derived using SF-12 mental and physical summary scores. Utili-
ties were derived from SF-6D preference scores and used to calculate cost per quality-
adjusted life-year (QALY). RESULTS: Of 53,524 respondents, 3,669 were assigned 
to the GAD group. GAD respondents accrued considerably higher direct (medication 
and health care resources) plus indirect (work productivity loss) costs (per person/
year) versus controls across pooled European countries (c5,308.80 vs. c2,441.10; P 
< 0.0001) and for each country (France c6,083.70 vs. c2,896.30; Germany c12,797.00 
vs. c4,876.10; UK c4,021.70 vs. c2,011.20; Italy c3,514.50 vs. c1,869.60; Spain 
c5,051.70 vs. c1,954.80; P < 0.0001 vs. controls within each country). Direct costs 
were driven by hospitalizations and psychologist/psychiatrist visits. Total costs 
increased with GAD severity from c4,094.00 for respondents with mild GAD to 
c7,753.10 for those with severe GAD. HRQoL was signiﬁ cantly poorer for GAD 
versus non-GAD respondents (P < 0.0001). Costs/QALY increased with GAD severity 
from c6,795 for mild GAD to c15,286 for severe GAD. CONCLUSIONS: The eco-
nomic and humanistic burden of illness of GAD across Europe is considerable and 
increases with the severity of disease.
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OBJECTIVES: Data concerning costs of patients with Attention deﬁ cit/hyperactivity 
disorder (ADHD) are scarce in Germany. Aim of this claims data analysis was to 
examine the costs of ADHD from the perspective of the statutory health insurance. 
METHODS: Nation-wide claims data of a major statutory health insurance fund was 
used to evaluate the overall and ADHD-related costs of ADHD-patients in 2008. All 
costs for outpatient care, inpatient care, pharmaceuticals, rehabilitation, occupational 
therapy as well as devices and aids, and sick leave payments were analyzed. To cal-
culate ADHD-related costs the overall health care costs of the identiﬁ ed ADHD-
patients were compared to an age and gender matched control group. RESULTS: 
Based on the used identiﬁ cation algorithm 30,264 ADHD-patients were identiﬁ ed. 
Mean overall costs of c3802 in the year 2008 were incurred from the health insurance 
perspective. c1704 (45%) were incurred by occupational therapy as well as devices 
and aids, and c779 (20%) were due to inpatient care; c751 (20%) resulted from 
outpatient care. Costs for pharmaceuticals were c483 (13%) and for rehabilitation 
were c35 (≤1%). Costs for sick leave payments came to c50 (1%). The matched 
control group contains 404,565 patients. Compared to this control group the incre-
mental mean costs of ADHD-patients were EUR 2,744. EUR 1,214 of these resulted 
from occupational therapy as well as devices and aids, c586 from inpatient care and 
c517 from outpatient care. Mean additional costs for pharmaceuticals in the ADHD-
group were c367. CONCLUSIONS: The major cost driver in ADHD from a health 
insurance perspective in Germany is occupational therapy as well as devices and aids.
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OBJECTIVES: To investigate the burden of depression in the Swiss population. The 
costs for the management of depressive patients will be analyzed for different severity 
classes of disease, based on the Hamilton depression rating scale, over a period of 12 
months following diagnosis. METHODS: A prospective, multicentre, non-interven-
tional study in psychiatrist practices was carried out. Patients who have been diag-
nosed with depression in the last three years were included. Patient’s characteristics 
and resource utilization in the ﬁ rst twelve months after diagnosis were collected. Costs 
analysis, subdivided in direct and indirect costs, was performed for three depression 
classes (mild, moderate, severe), according to the Hamilton depression score (HAMD-
17). Costs were also extrapolated to the national level. RESULTS: A total of 556 
patients were included. Hospitalization and hospitalization days were directly corre-
lated with disease severity (P < 0.001). Medical resource utilization linked to depres-
sion and antidepressant treatments were also correlated to disease status. Severe 
patients reported a signiﬁ cantly higher number of workdays lost and were signiﬁ cantly 
more often in disability insurance. Total direct costs per person, mainly due to hos-
pitalization costs, were CHF 4,823 for mild, CHF 13,251 for moderate, and CHF 
22,138 for severe depressions. Indirect costs, mainly due to workdays lost, resulted in 
CHF 11,892 for mild, CHF 17,267 for moderate, and CHF 22,710 for severe depres-
sions. Extrapolation at national level resulted in a total burden of about CHF 11 
billion. CONCLUSIONS: The burden of depression in Switzerland was estimated to 
be around CHF 11 billion. Costs of depression were directly related to disease severity. 
However, since many depressions remain unreported and since this analysis only 
included individuals between 18 and 65 years of age, it is reasonable to suppose that 
the total burden of depression may be even greater.
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OBJECTIVES: Major depressive disorder (MDD) is a leading cause of disability, 
morbidity, and mortality worldwide. The lifetime prevalence in the US is 17%. Treat-
ment resistant depression (TRD) is generally deﬁ ned as failure to achieve remissions 
